Insmed has been granted a patent for a dry powder composition of treprostinil prodrugs for treating pulmonary hypertension. The composition includes specific percentages of a compound, DSPE-PEG2000, leucine, and a sugar, and is administered via inhalation using a dry powder inhaler. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of September 2023 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Treating pulmonary hypertension with a dry powder composition
A recently granted patent (Publication Number: US11759425B2) describes a method for treating pulmonary hypertension in patients. The method involves administering a dry powder composition to the lungs of the patient using a dry powder inhaler. The dry powder composition consists of specific ingredients in specific amounts.
The dry powder composition includes a compound of Formula (I), which is present in the composition at a concentration ranging from about 0.1 wt % to about 3 wt %. Additionally, the composition includes DSPE-PEG2000, which is present at a concentration ranging from about 0.03 wt % to about 2.1 wt % of the total weight of the dry powder composition. The DSPE-PEG2000 can be distearoylphosphatidylethanolamine-polyethylene glycol 2000 or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol 2000.
The dry powder composition also contains leucine and mannitol. The leucine is present in the composition at a concentration ranging from about 18 wt % to about 33 wt % of the total weight of the dry powder composition. The mannitol is present at a concentration of about 68.45 wt %.
The method of administration involves aerosolizing the dry powder composition and delivering it to the lungs of the patient through inhalation. The aerosolized dry powder composition consists of particles with a mass median aerodynamic diameter (MMAD) ranging from about 1 µm to about 3 µm, as measured by Next Generation Impactor. The aerosolized dry powder composition also has a fine particle fraction ranging from about 30% to about 60%, as measured by Next Generation Impactor.
The method is specifically intended for the treatment of pulmonary hypertension, including pulmonary arterial hypertension, idiopathic pulmonary arterial hypertension, and pulmonary hypertension associated with interstitial lung disease.
This patent provides a specific method for treating pulmonary hypertension using a dry powder composition administered via inhalation. The composition includes specific ingredients in specific concentrations, and the method of administration ensures effective delivery of the composition to the lungs. This method may offer a new approach to treating pulmonary hypertension, potentially improving patient outcomes in this condition.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
